Lung Cancer

Finding the right balance between cancer-induced fatigue and immune-oncology–induced fatigue and doing enough exercise to improve general health and better cancer outcomes is a fundamental part of treating patients with cancer. Finding this balance for patients with NSCLC receiving immune-oncology therapy is a key element of overall care for these patients.

Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant sotorasib accelerated approval for patients with KRAS^G12C mutation–positive NSCLC.

Sotorasib showed encouraging anticancer activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.

Immunotherapy and targeted therapy have resulted in improved survival rates in patients with NSCLC over the past decade.

Multidisciplinary tumor board members work closely to make the best clinical decisions for their patients with cancer to improve patient and institutional outcomes. Their decisions should be based on the clinical data of each patient in line with their own clinical and institutional guidelines.

Recently released results using liquid biopsy shows KRAS G12C mutation in patients with NSCLC can be lost or acquired at progressive disease.

Social listening can offer investigators valuable information about unmet patient needs and concerns regarding their cancer treatment and to direct future research.

Researchers found a large underrepresentation gap among minority populations across major cancer types in clinical trials.

Improved understanding of self-care behaviors in patients with cancer who take oral anticancer medications can help healthcare professionals support patient medication adherence.

A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests.